JAMES XUE , Ph.D. , M.B.A.


Dr. James Xue is a veteran entrepreneur with extensive experience spans from US to China and from small biotech to multi-national biopharmaceutical companies. Over the last two decades, Dr. Xue led or was involved in several start-up companies and situations as well as managed sizable business and operations that contributed to his unique insight and deep knowledge in the biotech industry.

Dr. Xue built his biotech career by working for some of world’s most innovative companies in the San Francisco Bay Area and the Boston Area. Prior to CANbridge, he was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities.  For five years he was founding general manager of Genzyme China during which he managed the launch of several life-saving drugs for the treatment of hematologic cancer and rare metabolic diseases in China including Thymoglobuline® and Cerezyme®. Dr. Xue was recognized as a distinguished expert entrepreneur by the “the Recruitment Program of Global Experts”.

Dr. Xue holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He received executive training from INSEAD and Wharton Business School. Dr. Xue is a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School.  He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.



Glenn brings more than 15 years of experience in the healthcare sector globally, as an investor, investment banker, and strategy consultant.  Before joining CANbridge Glenn was Director, Healthcare Investment Banking at China Renaissance, where he advised Greater China and US life science companies on cross-border M&A and capital raising activities.  Prior to this, Glenn spent more than a decade investing in the healthcare sector globally. Most recently, he was Senior Analyst and Portfolio Manager at Leerink Capital. Before Leerink, Glenn was Senior Analyst at Citadel’s Surveyor Capital, its global equity long/short multi-manager strategy and Senior Healthcare Specialist, at Fidelity Investments, where he contributed to the global healthcare research effort for the overall Fidelity funds complex and supported the growth of the Fidelity healthcare team’s dedicated assets. 

His professional experience also includes strategy consulting and M&A investment banking. Glenn received a Bachelor of Science in Business with a finance concentration from Indiana University and a Master of Science in Global Finance Analysis from Bentley University’s McCallum Graduate School of Business, where he graduated with High Distinction.



Prior to founding his consulting practice, Dr. Cox was Chief Medical Officer for Editas Medicine, in Cambridge, where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, resulting in the first IND approval for in vivo delivery of CRISPR/Cas9 gene editing.  Dr. Cox also had a long stint at Sanofi Genzyme, also in Cambridge, culminating as Vice President, Rare Disease Clinical Development, where he oversaw multiple global rare disease clinical development programs, including Cerdelga®; olipudase alfa; Hectoral®; Cerezyme®, and Aldurazyme®, as well as Elaprase® in Asia, among others. Before then, Dr. Cox held several senior medical R&D positions at Genzyme and was the company’s first clinical geneticist recruited to oversee human clinical development programs for rare genetic diseases.  

Dr. Cox is a board-certified clinical geneticist and pediatrician who trained at Boston Children’s Hospital, where he remains on staff and continues to see patients with genetic diseases.  He earned an MD and PhD in Biology from the University of California at San Diego, and a Bachelor of Arts in Biology, from Harvard College. He holds multiple patents and awards and has authored scores of peer-reviewed publications, presentations and book chapters.



Mr. Cheresky has nearly 20 years’ business leadership experience in the biotechnology industry. Most recently, he was Vice President, Emerging Markets at Bioverativ, a Sanofi company, in Boston, MA, where he established regional structures for emerging markets and oversaw country launches in multiple emerging markets, including Australia, Columbia and Taiwan. Before then, Mr. Cheresky was Executive Director, Routes -to-Care Strategy, Ultragenyx Pharmaceuticals, in Novato, CA, where he developed a strategy for improving patient treatment access and provided direction to the medical field team. Prior to that, he was Regional Vice President – Latin America, for Synageva Biopharma, in Boston, MA, responsible for all Latin American operations, including clinical trial programs and regulatory affairs in Brazil, Argentina, Colombia and Mexico, where he oversaw the regulatory submission and approval for Kanuma®. Mexico was the third country to gain Marketing Authorization for Kanuma® worldwide. Earlier, Mr. Cheresky held multiple international positions at Genzyme Corporation, in Boston, MA

Mr. Cheresky holds a Master of Business Administration, from the University of North Carolina Kenan-Flagler Business School, Chapel Hill, and Bachelor of Science, Marketing, from the Universidad Argentina de la Empresa, Buenos Aires, Argentina.



Jeff brings with him 23 years of extensive experience in pharmaceutical finance management and operations. Prior to joining CANbridge, he was with Sanofi China for 5 years and most recently Senior Director, Head of Business Controlling, China Pharma & CHC at Sanofi China.  His responsibilities covered 6 BUs with combined revenues of 2 billion euros and a team with 20 staffs.  Between 2013 and 2016, He was Pharma Controlling Director and responsible for P&L and OPEX driven financial performance, operations, planning, budgeting, forecasting and reporting, control and compliance.  As the China pharma finance lead with a team of 15 staffs, Jeff partnered with country GM and BU heads,implemented systems and processes to ensure business growth and provided decision support.  Prior to Sanofi, Jeff built his solid career in pharmaceutical finance at GSK for almost 18 years. He started as Assistant Account at Glaxo Wellcome (which became GSK after the merger between Glaxo Wellcome and SmithKline Beechem in 2001) Hong Kong in 1995.  Over the years he progressed his career in financial accounting, FP&A, reporting and operations with increasing responsibilities spanning from GSK Hong Kong to GSK China.  His last role at GSK was Senior Finance Manager for GSK China, where he led the Finance Business Partner Team and supported 6 Rx Business Units and Hong Kong with combined revenues of around 800M euros in 2012. 

Jeff holds a bachelor’s degree in Business Administration with a major in Accounting from University of Wisconsin, Madison in the U.S.  He is also a Certified Public Accountant (Member of AICPA and HKICPA).



Minnie brings over 15 years of medical affairs and clinical development experience in multiple disease areas, including rare diseases. Prior to joining CANbridge, Minnie was the Country Medical Head of Shire China for two years (2018-2019), where she built up the clinical development, medical affairs, and clinical operations teams to a staff of 17. Minnie was responsible for hiring, budgeting, clinical development program and pipeline introduction, medical affairs strategy, new product launch planning, and product prioritization. She oversaw clinical trials for hemophilia, immunology, neurosurgery, ophthalmology, lysosomal storage disorders, and medical devices. Minnie interacted with CDE and contributed to NDA filings for 3 drugs and 1 medical device. 

Before Shire, Minnie was Senior Medical Director , Head of the Immunology-Dermatology Therapeutic Area and the Medical Strategy and Excellence groups at Novartis China (2011-2017). During her tenure there, she took on roles of increasing responsibility and received numerous awards from Novartis for her strong medical leadership and innovation. Her team executed medical pre-launch programs for several specialty disease products, including Consentyx® (secukinumab, a monoclonal antibody directed against IL-17A) for psoriasis, psoriatic arthritis, and ankylosing spondylitis. She also developed and instituted qualitative and quantitative Medical performance measurement tools. She mentored several direct reports who went on to assume leadership roles at Novartis.

Minnie began her industry career at Merck US (2004-2011) working on the clinical development of Isentress® (Raltegravir, a HIV integrase strand transfer inhibitor) for HIV infection from Phase I to PhaseIIb. After its approval in US, Minnie was asked to transfer back to China and joined medical affairs anti-infective team to lead new product medical launches for the anti-fungal, Cancidas® (casponfungin acetate, an echinocandin that inhibits fungal cell wall synthesis), and the anti-bacterial, Invanze® (ertapenem, a b-lactam that inhibits peptidoglycan cross-links in the bacterial cell wall). She built the first regional Medical Science Liaison team for Merck China and quickly expanded the staff from 3 to 40. By the time she exited Merck, Minnie was the Franchise Manager of the Allergy and Immunology portfolio.

Minnie hold a Doctor of Management degree from NICE University in France, a Master degree in immunology from Temple University Medical school in US and Genetics from Shanghai Fudan University. While in Temple Medical school, she also received a certificate for completing a 2-year program in drug development.



Rebecca Zhang brings to the position considerable regulatory experience in China in oncology and rare diseases. Prior to joining CANbridge, she was the Head of Regulatory Affairs at I-Mab Biopharma Ltd. Co. where she focused on Oncology and Immunology. Under her leadership, I-Mab successfully achieved 6 IND applications and approvals by NMPA and 1 IND approval by US FDA in 2019 and 2020. Additionally, Rebecca Zhang led the RA team to provide end to end regulatory strategy support for all pipeline products from discovery to post approval stage in the I-Mab organization. Before joining I-Mab, she had more than 20 years regulatory affairs experience in several MNCs, including GSK, Sanofi, AZ and Johnson and Johnson where she led a large RA team to support China business in JNJ. Rebecca Zhang started her career as a physician in the China-Japan Friendship Hospital. 

Rebecca Zhang holds a BS in Beijing Traditional Chinese Medicine University.



Dr. Wei Zhang has 10 years’ experience in research and development of biologics. Before joining CANbridge, he worked in I-MAB Biopharma, responsible for the CMC lead of multi projects. He managed activities in CMC and cross-function collaboration to ensure the whole projects’ goals and milestones achieved. Previous experience also includes various role in Innovent, Agilent Technologies, Wuxi Biologics and VIVA Biotech etc., leading and participating activities for product development, business development, extended characterization of biologic, and biomarker discovery respectively. He expertized in CMC development, quality control and project management. 

Wei Zhang obtained his Ph.D. of Chemical Biology from Fudan University.



Jenny brings to the position considerable quality management experience in GMP. Prior to joining CANbridge, she worked for over 13 years at GE Healthcare (Shanghai). where she Led team responsible for the management of release activities and quality procedures in accordance with applicable regulatory and customer requirements, including complying with EU GMP, US cGMP and approved corporate standards and Procedures. Before GE, Jenny had two years of quality management experience in a biophama company. 

Jenny holds a MS in East China University of Science and Technology.



Lily brings with her 17 years of market access experience with a proven track record across multiple therapeutic areas at global pharmaceutical companies. Prior to joining CANbridge, she was Head of Central Market Access, Oncology & Rare Disease Products at Novartis China. She provided leadership and operational oversight to address product value to payer and obtain their recognition in preparations Revolade, Jakavi and Exjade for the 2019 NRDL negotiation that is still ongoing. She played a key role in execution of the negotiation of NRDL listing of Tasigna, Zykadia, Votrient and Sandostatin LAR, contributing to significant revenue growth. Before Novartis, she was with Novo Nordisk China for 7 years most recently as Associated Director of Innovative Access and Market Access Operations. She led a successful campaign that resulted in the listing of Victoza in 2017 NRDL and no significant price cut of NovoSeven. She was able to create a PRDL window for Novo products in Tianjin by leveraging Novo’s manufacturing facility locally. In her earlier professional years Lily held various positions in market access and medical information and government affairs at GSK, Pfizer, Novartis and Xi’an Janssen. 

Lily obtained her bachelor’s degree in marketing and sales from North East University.



Chris has over 17 years of bio-pharmaceutical experience in HR management in an all-round way, including 11 years of professional experience in Human Resource Management of a US listed company. Prior to joining CANbridge, Chris held several HR management positions at Sinovac Biotech Ltd. (Nasdaq GSM: SVA) , she has rich experience on recruiting , and in charge of other important HR functions. During those 11 years, staff member increased from 25 to more than 600. Sinovac developed from one single company to a Group, with several subsidiary companies and JV companies. Prior to CANbridge, Chris was the HR Director of Huadu Biotech Ltd.

Chris graduated with a Master Degree in Human Resource Management from RenMin University of China.

Strategic Advisory Board



Mike Glynn is a seasoned global executive with over 40 years of general management and commercialization experience in Asia Pacific, Japan, Middle East, Latin America and the United States.  He has an impressive track record in start-up, turnaround, rapid growth, and organizational development situations.

His employment experience includes three years as SVP Global Commercial Operations at Synageva prior to its acquisition by Alexion; one year as EVP and Chief Commercial Officer at Pacific Biosciences; five years as SVP and Regional President Japan and Asia Pacific at Genzyme; seven years at Boston Scientific, two as Division President of Endovations, one as VP and General Manager Asia, Middle East and Turkey, and four as VP and General Manager Asia Pacific.  Earlier in his career he spent 10 years at Baxter International in various functional management roles in Australia and the United States.

At Genzyme, Mike was responsible for the overall P & L and direction of Genzyme’s business in Japan-Asia Pacific with over $500 million in sales and over 600 employees.  Revenues grew from $186 million in 2007 to just over $500 million in 2011 with a similar growth in profits.  At Boston Scientific he was responsible for approximately $200 million in sales and 420 employees in Asia.  During his tenure sales increased at a compounded annual growth rate of just over 30% and operating income increased at a CAGR of 182%. 

Mike has a MBA from Macquarie University, Australia and a B.Sc. and Diploma in Education from the National University of Ireland.



Mr. Geraghty is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) program, under which the company supported innovative development programs on a non-commercial basis. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Pieris Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company. 

A graduate of the Yale Law School, Mr. Geraghty holds a M.S. from the University of Pennsylvania and a B.A. from Georgetown University.



Dr. Gregory has a long and distinguished career in research and discovery and pharmaceutical industry leadership. Most recently, he was Executive VP and Chief Scientific Officer at ImmunoGen Inc., in Waltham, MA, where he was responsible for research leading to new antibody-based cancer therapeutics.  Prior to joining ImmunoGen, Dr. Gregory was Head of the Sanofi-Genzyme R&D Center, in Cambridge, MA, where he oversaw R&D in rare diseases, multiple sclerosis, immune disorders and tissue protection/regenerative medicine.  Before then, Dr. Gregory held a variety of positions at Genzyme Corporation, in Framingham, MA, including: Senior Vice President, Head of Research, where he was responsible for early R&D in all therapeutic areas at Genzyme and Vice President, Gene Therapy, where he directed programs in cancer immunotherapy, gene therapies for genetic diseases and cardiovascular gene therapy.   Dr. Gregory started his professional career at Genzyme Corporation as a Research Scientist in Molecular Biology, where his group was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and determine the molecular defect caused by the most common mutation of CFTR.

Dr. Gregory has co-authored over 60 peer-reviewed publications and holds 23 patents in the area of biotechnology.  He is a Fellow of the American Institute for Medical and Biological Engineering.

Dr. Gregory holds a Bachelor of Science in Biochemistry, from Virginia Polytechnic Institute and State University (Virginia Tech), in Blacksburg, VA, and a PhD in Biochemistry, from the University of Massachusetts, in Amherst, MA.



Iain Baird has worked in the pharmaceutical industry for 29 years. He started work for ICI which later became Zeneca and then AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2003 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees’. In 2006 Iain was one of the principles that established Avecia Vaccines in which he led the manufacturing and supply groups in the development of vaccines against anthrax and plague. 

Since 2010 Iain has been an independent consultant assisting clients in the development of their clinical products and has been involved in 3 successful BLA applications and 3 NDA applications as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections, preparing them for the inspections, supporting them during the inspections and in their successful responses. 

Iain specializes in working with the founders/CEO’s of companies with innovative products and services and has been working with CANbridge CEO James Xue since the start of 2013 assisting in the evaluation of product candidates that could be developed in the Chinese market. During that time, Iain has also worked with the founder of Gallus in the negotiation and establishment of Gallus Biopharmaceuticals, a pure play CDMO, and subsequently has worked with the founder of Brammer Bio for the development and manufacturing of viral vectors.



Founder, President of Tigermed, M.D., Ph.D., E.M.B.A.

EMBA of Guanghua School of Management, Peking University, obtained PhD in Oxford University UK.

Over 10 years’ experience in medical and regulatory affairs with global pharmaceutical industries.

The Former medical director in Shanghai Roche for 6 years.



Dr. Goldberg joined CANbridge as Acting Chief Medical Officer in 2015. He has been a member of the company's Advisory Board since 2013. Dr. Goldberg brings to CANbridge over 30 years of clinical and industry experience as a seasoned oncologist, hematologist and corporate medical/regulatory strategist.

Prior to CANbridge, he was Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation. Dr. Goldberg joined Synageva in 2011 from Genzyme Corporation, where he had most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of medicines such as Fabrazyme®, Aldurazyme®, Myozyme®, Lumizyme®, and Mozobil®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute. He holds appointments at Brigham and Women's Hospital and Dana Farber Cancer Institute and is also an Associate Professor of Medicine (part time) at Harvard Medical School.

Dr. Goldberg received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School. He holds Board appointments at Immunogen Corporation, Idera Pharmaceuticals, Glycomimetics, aTyr Pharma, Blueprint Medicines, and the American Cancer Society, New England Division.